CL
HRTX icon

CSS LLC’s Heron Therapeutics HRTX Stock Holding History

CSS LLC’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-26,500
Closed -$74K – 1107
2022
Q2 		$74K Buy
+26,500
New +$106K ﹤0.01% 915
2020
Q3 		– Sell
-8,400
Closed -$124K – 830
2020
Q2 		$124K Buy
+8,400
New +$138K 0.01% 530

Other funds holding HRTX

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

CSS LLC's HRTX Position: Q4 2022 in Review

CSS LLC sold out of Heron Therapeutics (HRTX) in Q4 2022, closing a stake of 9,000 shares — an estimated $38K sold.

CSS LLC first reported a position in HRTX in Q2 2020 and held it in 8 quarters. The position peaked at $622K in Q1 2021. 176 funds tracked by Wall St. Rank hold HRTX as of Q4 2022.

  • CSS LLC reported no remaining Heron Therapeutics position as of Q4 2022 after selling out during the quarter.
  • CSS LLC sold 9,000 Heron Therapeutics shares in Q4 2022, an estimated $38K.
  • CSS LLC first reported a position in Heron Therapeutics in Q2 2020 and held it in 8 quarters.
  • CSS LLC's Heron Therapeutics position peaked at $622K in Q1 2021.
  • 176 funds tracked by Wall St. Rank held Heron Therapeutics as of Q4 2022.

Based on CSS LLC's 13F filing for Q4 2022, filed 14 Feb 2023.